BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 33724586)

  • 1. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions.
    Fang L; Arvind D; Dowlati A; Mohamed A
    J Neuroendocrinol; 2021 Mar; 33(3):e12943. PubMed ID: 33724586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
    Xu JX; Wu DH; Ying LW; Hu HG
    World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
    Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
    Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
    Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
    Kawasaki K; Fujii M; Sato T
    Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management.
    Panzuto F; Massironi S; Partelli S; Campana D; Rinzivillo M; Invernizzi P; Andreasi V; Lamberti G; Falconi M
    Surg Oncol; 2020 Dec; 35():141-148. PubMed ID: 32877883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Yin F; Wu ZH; Lai JP
    World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intervention in gastro-enteropancreatic neuroendocrine tumours.
    Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).
    Orgera G; Krokidis M; Cappucci M; Gourtsoyianni S; Tipaldi MA; Hatzidakis A; Rebonato A; Rossi M
    Cardiovasc Intervent Radiol; 2015 Feb; 38(1):13-24. PubMed ID: 25366087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Consensus and controversy of endoscopic diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors].
    Chen H; Chen Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):982-986. PubMed ID: 28900987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy].
    Ye C; Yuan CH; Li G; Zheng L; Xiu DR
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):866-871. PubMed ID: 31694137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of gastro-entero-pancreatic neuroendocrine tumours (GEP NET): an introduction.
    Van Hootegem P; Borbath I; Verslype C
    Acta Gastroenterol Belg; 2009; 72(1):27-8. PubMed ID: 19402367
    [No Abstract]   [Full Text] [Related]  

  • 14. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
    Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
    Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
    Fazio N; La Salvia A
    Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.
    Verbeek WH; Korse CM; Tesselaar ME
    Eur J Endocrinol; 2016 Jan; 174(1):R1-7. PubMed ID: 26162406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
    Ooki A; Osumi H; Fukuda K; Yamaguchi K
    Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for gastro-enteropancreatic endocrine tumours.
    O'Toole D; Hentic O; Corcos O; Ruszniewski P
    Neuroendocrinology; 2004; 80 Suppl 1():79-84. PubMed ID: 15477723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on gastroenteropancreatic neuroendocrine tumors.
    Andreasi V; Partelli S; Muffatti F; Manzoni MF; Capurso G; Falconi M
    Dig Liver Dis; 2021 Feb; 53(2):171-182. PubMed ID: 32912771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.